Has the IPO window closed?

September 30, 2016 Christoph Graener

After outperforming the rest of the field for three straight years, the end of Q2 showed a decided chill in the market toward recent biotech IPOs. Has the window of opportunity closed? If so, what are the ramifications for those who had long anticipated debuts but are currently trading below issue price? Will we see increased partnerships with pharma to fund programs and operations? See a candid discussion on what this will mean for companies looking to fund in the future, for those still in line to IPO by year end and for those now facing the ramifications of falling share prices.

Moderator: John Carroll – Endpoints

  • Christiana Bardon – MPM Capital, Oncology Impact Fund
  • David Sabow – Silicon Valley Bank
  • Simos Simeonidis – RBC Capital Markets

Related Posts

No related posts.

Previous Article
What makes a serial entrepreneur so successful and what makes them tick?

Who are the top serial entrepreneurs in biotech? What kind of person does it take to enter a company at the...

Next Article
Johnson & Johnson Innovation pushes for digital health partnerships
Johnson & Johnson Innovation pushes for digital health partnerships

Johnson & Johnson sees digital health technology as one part of a larger mix of solutions as the industry m...